About Relypsa
Relypsa is a Healthcare company based in Redwood City (United States) founded in 2007, and was acquired by Galenica in July 2016. Non-absorbed polymeric drugs for cardiovascular and renal diseases are developed. Relypsa has raised $207.43 million across 9 funding rounds from investors including Credit Suisse, New Leaf Venture Partners and Orbimed. The company has 284 employees. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include Tenaya Therapeutics, Cellino and MyoKardia; 3 of its 3 listed competitors have raised funding.
Company details
Relypsa was founded in 2007 and is headquartered in Redwood City, United States. Focus is placed on the development of novel non-absorbed polymeric drugs targeted at cardiovascular and renal diseases. Operations center on creating therapies for conditions such as hyperkalemia. The lead product, Veltassa (patiromer) for oral suspension, serves as a non-absorbed potassium binder for managing elevated potassium levels in patients.
- Headquarters Redwood City, United States
- Employees 284
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website relypsa.com
- Social LinkedIn X
- Acquired by Galenica (Jul 2016)
- Total Equity Funding$207.43M (USD)
in 9 rounds
- Latest Funding Round$150M (USD), Debt – Conventional
May 2016
- InvestorsCredit Suisse
& 10 more
- Employee Count284
- Acquired byGalenica
(Jul 2016)
Funding Insights of Relypsa
Relypsa has successfully raised a total of $207.43M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $150 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $207.43M
- Total Rounds 9
- Last Round Debt – Conventional — $150M
- First Round $100,000
(Nov 2007)
- Investors Count 10
All 9 funding rounds of Relypsa with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2016 | $150M | Debt – Conventional | – | – | |
| Jun 2014 | $35M | Debt – Conventional | – | – | – |
| Dec 2012 | $80M | Series C | – | – | |
| Sep 2010 | $70.13M | Series B | – | Orbimed | |
| Jul 2010 | $6M | Series A | – | – | – |
| Jun 2009 | $51.2M | Series A | – | – | |
| Aug 2008 | $45,000 | Seed | – | – | – |
| Nov 2007 | $100,000 | Debt – Convertible | – | – | – |
| Nov 2007 | $52,450 | Seed | – | – | – |
11 investors in total: 11 institutional.
Investors in Relypsa
Relypsa has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Credit Suisse, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
| siblingcapital.com | ||||
| mediphaseventure.com | ||||
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| cmea.com | ||||
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland |
Investor details for Relypsa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Relypsa
5 dated milestones of Relypsa across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Relypsa is founded.
- Funding First funding round of $100K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $150.0M.
- Exit Acquired by Galenica.
Competitors of Relypsa
Relypsa has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Cellino and MyoKardia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. |
Detailed competitors of Relypsa
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Relypsa
Websites that share an audience with Relypsa (relypsa.com).
Websites whose visitors overlap most with Relypsa. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
research.arizona.edu | research.arizona.edu | 100% | – | ||
provost.uoregon.edu | provost.uoregon.edu | 98% | – | ||
binghamtonsa.org | binghamtonsa.org | 96% | #3,849,137 | – | |
vote.psu.edu | vote.psu.edu | 96% | – |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Relypsa (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Relypsa
Complete news archive for Relypsa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relypsa
Relypsa was founded in 2007.
Relypsa is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Relypsa is a funded company, having raised a total of $207.43M across 9 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $100K, raised on Nov 2007.
Relypsa has 284 employees.
Relypsa was founded in 2007 and is headquartered in Redwood City, United States. Focus is placed on the development of novel non-absorbed polymeric drugs targeted at cardiovascular and renal diseases. Operations center on creating therapies for conditions such as hyperkalemia. The lead product, Veltassa (patiromer) for oral suspension, serves as a non-absorbed potassium binder for managing elevated potassium levels in patients.
Relypsa's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Relypsa has 11 investors. Key investors include Credit Suisse, New Leaf Venture Partners, Orbimed, Galenica, and Athyrium Capital Management.
Yes. Relypsa was acquired by Galenica in July 2016.